The estimated Net Worth of Thomas Mc Eachin is at least $230 millier dollars as of 2 May 2017. Mr. Eachin owns over 4,500 units of RTI Surgical stock worth over $95,120 and over the last 9 years he sold RTIX stock worth over $0. In addition, he makes $135,000 as Independent Director at RTI Surgical.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. McEachin RTIX stock SEC Form 4 insiders trading
Thomas has made over 1 trades of the RTI Surgical stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 4,500 units of RTIX stock worth $19,575 on 2 May 2017.
The largest trade he's ever made was buying 4,500 units of RTI Surgical stock on 2 May 2017 worth over $19,575. On average, Thomas trades about 281 units every 0 days since 2015. As of 2 May 2017 he still owns at least 30,293 units of RTI Surgical stock.
You can see the complete history of Mr. Eachin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas McEachin biography
Thomas A. McEachin is Independent Director of the Company. Mr. McEachin joined the Board of Directors in December 2015. He has been retired since 2012. Prior to his retirement, he served in executive capacities with Covidien Surgical Solutions, a division of Covidien plc, from 2008 to 2012, first as Vice President, Finance from 2008 to 2011, and then as Vice President and Group Chief Financial Officer from 2011 to 2012. From 1997 to 2008, Mr. McEachin served United Technologies and its subsidiaries in various finance capacities. Prior to joining United Technologies, Mr. McEachin served in various executive capacities with Digital Equipment Corporation from 1986 to 1997 and Xerox Corporation from 1975 to 1986. Mr. McEachin holds a B.S. from New York University and an MBA from Stanford University. Mr. McEachin’s finance and executive management experience provides our Board of Directors with valuable financial reporting, compliance, accounting and controls, and corporate governance experience. Mr. McEachin also qualifies as an “Audit Committee Financial Expert.”
What is the salary of Thomas McEachin?
As the Independent Director of RTI Surgical, the total compensation of Thomas McEachin at RTI Surgical is $135,000. There are 4 executives at RTI Surgical getting paid more, with Jonathon Singer having the highest compensation of $2,188,310.
How old is Thomas McEachin?
Thomas McEachin is 67, he's been the Independent Director of RTI Surgical since 2015. There are no older and 9 younger executives at RTI Surgical.
What's Thomas McEachin's mailing address?
Thomas's mailing address filed with the SEC is 1301, Concord Terrace, Sunrise, Broward County, Florida, 33323, United States.
Insiders trading at RTI Surgical
Over the last 21 years, insiders at RTI Surgical have traded over $71,830 worth of RTI Surgical stock and bought 390,515 units worth $1,973,594 . The most active insiders traders include Jeffrey C Lightcap, Mark Stolper et Terry M. Rich. On average, RTI Surgical executives and independent directors trade stock every 138 days with the average trade being worth of $62,561. The most recent stock trade was executed by Jonathon M Singer on 12 December 2018, trading 50,000 units of RTIX stock currently worth $214,000.
What does RTI Surgical do?
RTI Surgical Holdings, Inc. engages in the provision of biologic, metal, and synthetic-based surgical implants. It offers implants in the following categories: extremities, orthobiologics, spine, sports medicine, and surgical specialties. The company was founded in February 1998 and is headquartered in Deerfield, IL.
What does RTI Surgical's logo look like?
Complete history of Mr. Eachin stock trades at RTI Surgical, Federal Realty Investment Trust et Pediatrix Medical Inc
RTI Surgical executives and stock owners
RTI Surgical executives and other stock owners filed with the SEC include:
-
Jonathon Singer,
Chief Financial Officer, Chief Operating Officer -
John Varela,
Executive Vice President - Global Operations -
Olivier Visa,
Vice President - OEM, Sports and Donor Services -
Shirley Weis,
Independent Director -
Thomas McEachin,
Independent Director -
Mark Stolper,
Lead Independent Director -
Paul Thomas,
Independent Director -
Nicholas Valeriani,
Independent Director -
Pawel Lewicki,
Director -
Scott Durall,
Chief Commercial Officer -
Bryan Cornwall,
Executive Vice President - Research and Clinical Affairs -
Stuart Simpson,
Chairman of the Board -
Molly Poarch,
Director, Corporate Communications & Investor Relations -
Jeffrey Lightcap,
Independent Director -
Brian Kushner,
Director -
Ryan Bartolucci,
Vice President - Finance, Corporate Controller -
Terry Rich,
President, Chief Executive Officer, Director -
Lyle P. Luedeman,
-
Dean H Bergy,
Director -
Street Healthcare Partners ...,
-
Christopher R Sweeney,
Director -
Curtis M Selquist,
Director -
Peter F Gearen,
Director -
Brian K Hutchison,
Chairman, President and CEO -
Camille Farhat,
Chief Executive Officer -
Robert P Jordheim,
Executive Vice President/CFO -
Roger W Rose,
Vice President Donor Services -
Johannes Wynand Louw,
Vice President Finance -
Kevin D Brandt,
EVP CCO-Domestic Direct -
Joshua H De Rienzis,
General Counsel -
Philip R Chapman,
Director -
Ned Hoye Villers,
Director -
Adrian J R Smith,
Director -
Caroline A Hartill,
V.P. Quality Assurance -
Julianne M Bowler,
Director -
Roy D Crowninshield,
Director -
Gregory P Rainey,
Director -
Neal B Freeman,
Director -
Michael J La Prade,
Vice President -
Holdings Inc Zimmer,
10% owner -
Roderick N Allen,
Vice President -
David J Simpson,
Director -
Guy L Mayer,
President -
Michael J Odrich,
Director -
Lee Robert Jr Johnston,
Vice President -
Udo Henseler,
Director -
Christie J Blakely,
Vice President -
Robert J Lane,
Vice President -
Tara Leigh Zerby,
VP, Xenograft Technologies -
Carolyn Shaffer,
Vice President, Human Resource -
Thomas F Rose,
Vice President and CFO -
Michael T Manley,
Director -
Louis E Barnes,
Vice President-Cardiovascular -
Charles Randal Mills,
V.P. of Business Development -
William Melendez,
Vice President, Research & Dev -
Jeffrey Michael Schumm,
Vice Pres. and General Counsel -
Joseph W Condon,
Vice President-Operations